Correlates of serum lipids and lipoproteine in Congolese patients with arterial hypertension

Cardiovascular Journal of South Africa

Volumn 16, Issue 5, 2005, Pages 249-255

  Lepira, F B ^a   M'Buyamba Kabangu, J R ^a   Kayembe, K P ^b   Nseka, M N ^a  

^a University of Kinshasa Hospital   (Congo)

^b UNIVERSITY OF KINSHASA   (Congo)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BLOOD DONOR; BLOOD PRESSURE; BODY MASS; CASE CONTROL STUDY; CHI SQUARE TEST; CHOLESTEROL BLOOD LEVEL; CONGO; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART RATE; HOSPITAL PERSONNEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE LINEAR REGRESSION ANALYSIS; OBESITY; OUTPATIENT DEPARTMENT; RISK FACTOR; STUDENT T TEST; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; URIC ACID BLOOD LEVEL; WAIST HIP RATIO;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONGO; CREATININE; DYSLIPIDEMIAS; FEMALE; FIBRINOGEN; HUMANS; HYPERTENSION; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; TRIGLYCERIDES; URIC ACID; WAIST-HIP RATIO;

EID: 29044443973     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: general considerations, the epidemiologic 1 transition, risk factors and the impact of urbanisation. Circulation 2001; 104: 2746-2753.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-2864.
3. Walker AR, Walker BF, Segal I. Some puzzling situations in the onset, occurrence and future of coronary heart disease in developed and developing populations particularly in sub-Saharan Africa. Br Med J 2004; 328(487): 1032.
4. Cooper RS, Amoah AG, Mensah GA. High blood pressure: the foundation for epidemic Cardiovascular Disease in African populations. Ethn Dis 2003; 13(2 Suppl.2): S49-52.
5. M'Buyamba-Kabangu JR, Fagard R, Staessen J, Lijnen P, Amery A. j Correlates of blood pressure in rural and urban Zaire. J Hypertens 1987; 5: 371-375.
6. Tambwe M, Mbala-Mukendi M, Dikassa LN, M'Buyamba-Kabangu JR. Morbidity and mortality in hospitalized Zairean adults. South Afr J Med 1995; 85: 74.
7. Mbaraga N, Longo-Mbensa B, Tshiani K. Arterial hypertension at the Teaching Hospital of Kinshasa. Trop Cardiol 1984; 10: 85-89.
8. M'Buyamba-Kabangu JR, Lepira FB, Fagard R, Lijnen P, Ditu M, Tshiani K. Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol 1986; 29: 523-527.
9. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334(2): 374-381.
10. Sowers JR, Frolich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88(1): 63-82.
11. Bonow RO, Gheorghiade M. The diabetes epidemic: A national and global crisis. Am J Med 2004; 116(5A): 2S-10S.
12. Bhakdi S, Lachner KJ, Hen SR, Torzewski M, Husmann M. Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb Haemost 2004; 91(4): 639-45.
13. Flesch M, Sachinidis A, Ko YD, Kraft K, Vetter H. Plasma lipids and lipoproteins and essential arterial hypertension. Clin Invest 1994; 72: 944-950.
14. Sander SE, Giles TD. Hypertension and lipids: lipid risk factors in the hypertension syndrome. Curr Hypertens Rep 2002; 4(6): 458-463.
15. Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens 2002; 11(5): 484-496.
16. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25: 155-161.
17. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med 1996; 156: 1952-1956.
18. Velliquette RA, Ernsberger P. Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 2003; 307(3): 1104-1111.
19. Guidelines subcommittee. World Health Organization - International Society of Hypertension. 1999 Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-508.
21. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Bieleli E, Muls E, Vansant G, Blaton V. Plasma lipoprotein(a) among Congolese subjects: atherothrombotic risk factor? Congo Med 2002; 3(8): 652-656.
23. Youmbissi TJ, Djoumbissi S, Nouadoui C, Ndobo P, Meli J. Lipid profile in a group of hypertensive black African Cameroonians. Med Afr Noire 2001; 48(7): 305-314.
24. Nyarko A, Adubofour K, Ofei F, Kpodonu J, Owusu S. Serum lipid and lipoprotein levels in Ghanaians with diabetes mellitus and hypertension. J Natl Med Assoc 1997; 89(3): 191-196.
25. Oyelola OO, Ajayi AA, Babalola RO, Stein ER. Plasma lipids, lipoproteins and apolipoproteins in Nigerian diabetes mellitus, essential arterial hypertension and hypertensive diabetic patients. J Natl Med Assoc 1995; 87(2): 113-118.
26. Adedeji OO, Onitri AC. Plasma lipids in Nigerian hypertensives. Afr J Med Sci 1990; 19: 281-284.
27. Kesteloot H, Oviasu VO, Abasohan AO, Olemu A, Cohn C, Lissena W. Serum lipid and apolipoprotein levels in a Nigerian population sample. Atherosclerosis 1989; 78: 33-38.
28. Onowogbu IC. Comparison of HDL and serum cholesterol levels in European and African community. Atherosclerosis 1979; 34: 49.
29. Donen D, Wietlisbach V, Bovet P, Shamlaye O, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Pub Hlth 2004; 4: 9.
30. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Metab Disord 2002; 26(Suppl 4): S15-20.
31. Davy KP, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp 2004; 286(5): R 803-813.
32. Grundy SM. Management of high serum cholesterol and related disorders in patients with coronary artery disease. Am J Med 1997; 102(2A): 15-22.
33. Hobbs FD. Primary prevention of cardiovascular disease: managing hypertension and hyperlipidemia. Heart 2004; 90(Suppl 4): iv 22-25.
34. Chapman N. New evidence in hypertension and hyperlipidemia. Heart 2004; 90(Suppl. 4): iv 14-17.
35. Geraci TS, Geraci SA. What ALLHAT tells us about treating high-risk patients with hypercholesterolemia and hypertension. J Cardiovasc Nurs 2003; 18(5): 389-395.
36. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symonidis AN, Pehlivanidis AN. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary Heart Disease. A subgroup analysis of the Greek atorvastatin and CHD evaluation (GREACE) study. J Clin Pathol 2004; 57(7): 728-734.
37. Pascot A, Lemieux I, Bergeron I, Tremblay A, Nadeau A, Prud'homme D, et al. HDL particle size: a marker of the gender difference in the metabolic risk profile. Atherosclerosis 2002; 160(2): 399-406.
38. Fogari R, Zoppi A, Marasi G, Vanasia A, Villa G. Association between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J Cardiovasc Risk 1994; 1: 341-345.
39. Palmieri V, Celentano A, Roman JM, De Simone G, Lewis MR, Best L, et al. Fibrinogen and preclinical echocardiographic target organ damage. The Strong Heart Study. Hypertension 2001; 38: 1068-1074.
40. Horio T, Miyazato J, Kamida K, Takiuchi S, Kawano Y. Influence of HDL cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 2003; 16(11): 938-944.
41. Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004; 13(4): 509-513.
42. Syvânne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in NIDDM. Lancet 1997; 350(Suppl.I): 20-23.
43. Ellison RC, Zhang Y, Qureshi MM, Knox S, Arnett DK, Province NA. Lifestyle determinants of HDL cholesterol. The National Heart, Lung and Blood Institute Family Heart Study. Am Heart J 2004; 147(3): 529-535.
44. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A. Genetics of HDL regulation in humans. Curr Opin Lipidol 2003; 14(3): 273-279.
45. Mukkerjee M, Shelly M. Variations in HDL cholesterol in relation to physical activity and Taq IB polymorphism of the CETP gene. Clin Genet 2004; 65(5): 412-418.
46. Zietz B, Harforth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-c levels in type 2 diabetes mellitus. FEBS Lett 2003; 545(2-3): 103-104.
47. Fried SK, Rao SP. Sugars, hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 2003; 78(4): 8735-880S.